Q-omics provides the consensus-scored GNG2 profile across patient tissues and cancer cell-line models. GNG2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GNG2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, GNG2 protein abundance shows 30,422 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where GNG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNG2 survival associations across molecular data types. GNG2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNG2 RNA expression–survival associations across cancer types. High GNG2 expression shows unfavorable associations in KIRP, but favorable associations in CESC, HNSC, PAAD, LAML and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GNG2 RNA expression.
This table summarizes GNG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GNG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNG2 shows lower tumor expression in COAD, LUAD, KICH and LUSC and higher tumor expression in KIRC and HNSC. The COAD box plot shows higher GNG2 RNA expression in normal versus tumor tissue (log2 FC = −1.791, t-test p < 0.001).
This table shows molecular features associated with GNG2 in patient tissues and cancer cell lines. In patient samples, GNG2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
